Advertisement
Teva Pharma Reaffirms FY23 Outlook - Update
(RTTNews) - While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
For fiscal 2023, the company still projects adjusted earnings in a range of $2.25 to $2.55 per share on revenues between $14.8 billion and $15.4 billion.
On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $2.40 per share on revenues of $15.06 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma
Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews
|
512 gün önce
Teva Pharma Guides FY24 Revenue Above Estimates; Intends To Divest API Business - Update
While reporting financial results for the fourth quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) initiated its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews
|
575 gün önce
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S
Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews
|
650 gün önce
Teva Pharma Boosts FY23 Revenue Outlook - Update
While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews
|
659 gün önce
Teva Pharma Boosts FY23 Revenue Outlook - Update
While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews
|
757 gün önce
Teva Recalls FENTANYL Buccal Tablets CII
Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews
|
850 gün önce
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer
Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.
RTTNews
|
1154 gün önce
Switzerland Logs Weaker Growth, Trims 2026 Outlook
The Swiss economy expanded modestly in the second quarter, as estimated earlier, and higher U.S. tariffs are set to push down growth prospects, the State Secretariat for Economic Affairs said Thursday. Gross domestic product grew 0.1 percent from the first quarter, unchanged from the flash estimate. Growth softened notably from 0.7 percent in the first quarter.
RTTNews
|
3 dakika önce
